Schulhoff & Co. Inc. Sells 1,060 Shares of Johnson & Johnson (NYSE:JNJ)

Schulhoff & Co. Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 43,499 shares of the company’s stock after selling 1,060 shares during the period. Johnson & Johnson accounts for 2.9% of Schulhoff & Co. Inc.’s portfolio, making the stock its 6th biggest position. Schulhoff & Co. Inc.’s holdings in Johnson & Johnson were worth $6,358,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Williams Financial LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $1,655,000. Lyell Wealth Management LP lifted its position in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Lyell Wealth Management LP now owns 7,332 shares of the company’s stock valued at $1,072,000 after buying an additional 267 shares in the last quarter. Guardian Wealth Management Inc. increased its holdings in Johnson & Johnson by 1.3% in the 2nd quarter. Guardian Wealth Management Inc. now owns 12,759 shares of the company’s stock worth $1,865,000 after acquiring an additional 161 shares in the last quarter. J.W. Cole Advisors Inc. lifted its holdings in Johnson & Johnson by 5.9% during the second quarter. J.W. Cole Advisors Inc. now owns 60,750 shares of the company’s stock valued at $8,879,000 after purchasing an additional 3,391 shares in the last quarter. Finally, OV Management LLC grew its position in shares of Johnson & Johnson by 1.8% in the second quarter. OV Management LLC now owns 7,229 shares of the company’s stock valued at $1,057,000 after purchasing an additional 129 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.52 on Friday. The company’s 50-day moving average is $159.55 and its two-hundred day moving average is $153.99. The firm has a market capitalization of $398.45 billion, a price-to-earnings ratio of 10.32, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the business posted $2.80 earnings per share. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, September 9th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.